KR101537830B1 - 고혈압 치료용 티아졸리딘디온 유사체 - Google Patents

고혈압 치료용 티아졸리딘디온 유사체 Download PDF

Info

Publication number
KR101537830B1
KR101537830B1 KR1020107008064A KR20107008064A KR101537830B1 KR 101537830 B1 KR101537830 B1 KR 101537830B1 KR 1020107008064 A KR1020107008064 A KR 1020107008064A KR 20107008064 A KR20107008064 A KR 20107008064A KR 101537830 B1 KR101537830 B1 KR 101537830B1
Authority
KR
South Korea
Prior art keywords
aliphatic
mmol
added
delete delete
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107008064A
Other languages
English (en)
Korean (ko)
Other versions
KR20100075915A (ko
Inventor
제라드 알. 콜카
로버트 씨. 가드우드
팀 파커
Original Assignee
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 filed Critical 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨
Publication of KR20100075915A publication Critical patent/KR20100075915A/ko
Application granted granted Critical
Publication of KR101537830B1 publication Critical patent/KR101537830B1/ko
Assigned to 씨리우스 테라퓨틱스, 엘엘씨 reassignment 씨리우스 테라퓨틱스, 엘엘씨 권리의 전부이전등록 Assignors: 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107008064A 2007-09-14 2008-09-15 고혈압 치료용 티아졸리딘디온 유사체 Active KR101537830B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97263907P 2007-09-14 2007-09-14
US60/972,639 2007-09-14

Publications (2)

Publication Number Publication Date
KR20100075915A KR20100075915A (ko) 2010-07-05
KR101537830B1 true KR101537830B1 (ko) 2015-07-17

Family

ID=40239575

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008064A Active KR101537830B1 (ko) 2007-09-14 2008-09-15 고혈압 치료용 티아졸리딘디온 유사체

Country Status (15)

Country Link
US (1) US8067450B2 (enExample)
EP (1) EP2203433B1 (enExample)
JP (1) JP5371988B2 (enExample)
KR (1) KR101537830B1 (enExample)
CN (1) CN101848901B (enExample)
AU (1) AU2008301905B2 (enExample)
BR (1) BRPI0817096B8 (enExample)
CA (1) CA2699289C (enExample)
ES (1) ES2398313T3 (enExample)
IL (1) IL204440A (enExample)
MX (1) MX2010002820A (enExample)
NZ (2) NZ597381A (enExample)
PL (1) PL2203433T3 (enExample)
RU (1) RU2486179C2 (enExample)
WO (1) WO2009038681A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454006B (zh) 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
EP2902026B1 (en) 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
CN101848901B (zh) 2007-09-14 2012-11-21 新陈代谢解决方案开发公司 用于治疗高血压的噻唑烷二酮类似物
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
EP2512470B1 (en) * 2009-12-15 2016-11-30 Octeta Therapeutics, LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CN102917705A (zh) * 2009-12-15 2013-02-06 新陈代谢解决方案开发公司 用于治疗肥胖症和其它代谢性疾病的ppar节制性噻唑烷二酮和组合
KR20120092712A (ko) * 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
US8912335B2 (en) * 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
PL2560956T3 (pl) 2010-04-19 2017-03-31 Octeta Therapeutics, Llc Nowa synteza związków tiazolidynodionowych
KR20130064742A (ko) * 2010-04-21 2013-06-18 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 티아졸리딘디온 유사체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2807662C (en) * 2010-08-10 2019-10-08 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
KR101857307B1 (ko) 2010-08-10 2018-05-11 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 티아졸리딘디온 화합물의 합성법
WO2012109495A1 (en) * 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
MX2016000724A (es) 2013-07-22 2016-04-13 Metabolic Solutions Dev Co Llc Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
EP3749292A1 (en) 2018-02-08 2020-12-16 ENYO Pharma Use of modulators of neet proteins for the treatment of infection
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) * 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
EP1210087A2 (en) 1999-04-29 2002-06-05 City of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
WO2001000579A1 (en) 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
HUP0400091A2 (hu) 2001-04-26 2004-06-28 Léciva, a.s. Eljárás antidiabetikus hatású pioglitazon előállítására
WO2003026586A2 (en) 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
WO2004007490A2 (en) 2002-07-16 2004-01-22 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
WO2004082715A1 (ja) * 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2005015477A (ja) * 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
WO2006035954A1 (en) 2004-09-28 2006-04-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
EP2902026B1 (en) 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
CN101454006B (zh) 2006-03-16 2012-12-26 新陈代谢解决方案开发公司 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物
CA2646170A1 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
CN101848901B (zh) 2007-09-14 2012-11-21 新陈代谢解决方案开发公司 用于治疗高血压的噻唑烷二酮类似物
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) * 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical and Pharmaceutical Bulletin. 1982. Vol.30, No.10, pp.3580-3600. *
Chemical and Pharmaceutical Bulletin. 1982. Vol.30, No.10, pp.3580-3600.*

Also Published As

Publication number Publication date
HK1146484A1 (en) 2011-06-10
ES2398313T3 (es) 2013-03-15
BRPI0817096A8 (pt) 2017-10-10
US8067450B2 (en) 2011-11-29
BRPI0817096B8 (pt) 2021-05-25
CA2699289A1 (en) 2009-03-26
JP2010539171A (ja) 2010-12-16
AU2008301905A1 (en) 2009-03-26
CN101848901A (zh) 2010-09-29
CN101848901B (zh) 2012-11-21
MX2010002820A (es) 2010-04-01
RU2486179C2 (ru) 2013-06-27
JP5371988B2 (ja) 2013-12-18
PL2203433T3 (pl) 2013-04-30
KR20100075915A (ko) 2010-07-05
AU2008301905B2 (en) 2013-06-27
RU2010114727A (ru) 2011-10-20
BRPI0817096B1 (pt) 2020-11-10
NZ597381A (en) 2013-03-28
US20100222399A1 (en) 2010-09-02
EP2203433B1 (en) 2012-10-31
NZ583889A (en) 2012-01-12
BRPI0817096A2 (pt) 2017-05-02
CA2699289C (en) 2016-01-19
WO2009038681A1 (en) 2009-03-26
IL204440A (en) 2013-05-30
EP2203433A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
AU2008301905B2 (en) Thiazolidinedione analogues for the treatment of hypertension
KR101475955B1 (ko) 티아졸리딘디온 유사체
EP2512470B1 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
EP2513070B1 (en) Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
JP2010539171A5 (enExample)
WO2010105048A9 (en) Thiazolidinedione analogues
WO2011084459A1 (en) Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
EP2001469A2 (en) Thiazolidinedione analogues
KR20130064742A (ko) 티아졸리딘디온 유사체
US8304441B2 (en) Thiazolidinedione analogues for the treatment of metabolic diseases
AU2013200104B2 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
HK1146484B (en) Thiazolidinedione analogues for the treatment of hypertension
HK1178066A (en) Thiazolidinedione analogues

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100413

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130912

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140929

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150420

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150713

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150713

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190617

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190617

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200618

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210617

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250616

Start annual number: 11

End annual number: 11